Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05145413 is registered in ClinicalTrials.gov with Karuna Therapeutics, Inc., a Bristol Myers Squibb company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 12, 2021
- Completion date
- March 19, 2025
- Enrollment
- 396 (actual)
- Sites
- 166
Conditions
As the registry lists them; a condition with its own page is linked.